Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lu Si

Showing results (161-170 of 230) with videos related to

Pageof 23
Sort By:
Clinical and Translational Medicine|January 6, 2025
Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysisJie Dai, Tianxiao Xu, Lifeng Li, et al.
Innovation (Cambridge (Mass.))|June 17, 2024
IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinomaChuanliang Cui, Juan Li, Yue Yang, et al.
Journal of Cancer|February 6, 2019
Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation SequencingJiayi Yu, Xiaowen Wu, Junya Yan, et al.
Cancer Research Communications|May 2, 2024
Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical ImplicationsJie Dai, Jia Jia, Fanshuang Zhang, et al.
BMC Cancer|May 20, 2022
Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I studyLi Zhou, Xiaowen Wu, Zhihong Chi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2023
Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trialXuan Wang, Xiaowen Wu, Yue Yang, et al.
Experimental Hematology & Oncology|June 2, 2026
Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapyQian Zhao, Yu Du, Lifeng Li, et al.
Frontiers in Immunology|October 28, 2022
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 studyLu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Frontiers in Surgery|January 20, 2022
Surgical Outcomes of Vaginal or Cervical MelanomaHui Tian, Xuan Wang, Bin Lian, et al.
Med (New York, N.Y.)|March 20, 2025
Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 studyXieqiao Yan, Juan Li, Huayan Xu, et al.
Pageof 23

Showing results (161-170 of 230) with videos related to

Sort By:
Pageof 23
Clinical and Translational Medicine|January 6, 2025
Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysisJie Dai, Tianxiao Xu, Lifeng Li, et al.
Innovation (Cambridge (Mass.))|June 17, 2024
IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinomaChuanliang Cui, Juan Li, Yue Yang, et al.
Journal of Cancer|February 6, 2019
Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation SequencingJiayi Yu, Xiaowen Wu, Junya Yan, et al.
Cancer Research Communications|May 2, 2024
Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical ImplicationsJie Dai, Jia Jia, Fanshuang Zhang, et al.
BMC Cancer|May 20, 2022
Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I studyLi Zhou, Xiaowen Wu, Zhihong Chi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2023
Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trialXuan Wang, Xiaowen Wu, Yue Yang, et al.
Experimental Hematology & Oncology|June 2, 2026
Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapyQian Zhao, Yu Du, Lifeng Li, et al.
Frontiers in Immunology|October 28, 2022
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 studyLu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Frontiers in Surgery|January 20, 2022
Surgical Outcomes of Vaginal or Cervical MelanomaHui Tian, Xuan Wang, Bin Lian, et al.
Med (New York, N.Y.)|March 20, 2025
Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 studyXieqiao Yan, Juan Li, Huayan Xu, et al.
Pageof 23